1. Home
  2. BHVN vs NBTX Comparison

BHVN vs NBTX Comparison

Compare BHVN & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biohaven Ltd.

BHVN

Biohaven Ltd.

HOLD

Current Price

$13.04

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

HOLD

Current Price

$20.97

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHVN
NBTX
Founded
2013
2003
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
BHVN
NBTX
Price
$13.04
$20.97
Analyst Decision
Buy
Strong Buy
Analyst Count
15
1
Target Price
$29.43
$8.00
AVG Volume (30 Days)
3.7M
36.0K
Earning Date
03-02-2026
09-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$11,930,711.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$145.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.48
$2.93
52 Week High
$44.28
$30.35

Technical Indicators

Market Signals
Indicator
BHVN
NBTX
Relative Strength Index (RSI) 62.98 49.74
Support Level $10.35 $19.61
Resistance Level $12.87 $22.22
Average True Range (ATR) 1.25 1.05
MACD 0.20 -0.06
Stochastic Oscillator 96.61 46.32

Price Performance

Historical Comparison
BHVN
NBTX

About BHVN Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Share on Social Networks: